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In order to understand and find therapeutic strategies for neurological disorders, disease models that recapitulate the
connectivity and circuitry of patients’ brain are needed. Owing to many limitations of animal disease models, in vitro
neuronal models using patient-derived stem cells are currently being developed. However, prior to employing neurons
as a model in a dish, they need to be evaluated for their electrophysiological properties, including both passive and
active membrane properties, dynamics of neurotransmitter release, and capacity to undergo synaptic plasticity. In this
review, we survey recent attempts to study these issues in human induced pluripotent stem cell-derived neurons.
Although progress has been made, there are still many hurdles to overcome before human induced pluripotent stem
cell-derived neurons can fully recapitulate all of the above physiological properties of adult mature neurons. Moreover,
proper integration of neurons into pre-existing circuitry still needs to be achieved. Nevertheless, in vitro neuronal stem
cell-derived models hold great promise for clinical application in neurological diseases in the future.Introduction
The complexity of the human central nervous system
and its inaccessibility to direct studies make its modeling
necessary in order to investigate physiological and
pathological processes occurring in it. Animal disease
models have been introduced to study pathophysio-
logical processes and eventually develop new treatments.
However, the use of animal models has drawbacks, in-
cluding high costs of maintenance and difficulties to
fully mimic the characteristics of a human neurological
disease. In vitro models using patient-derived cells are cur-
rently emerging to study neuropathologies and test pos-
sible treatments, as the in vitro system is more scalable,
controllable and cheaper. In particular, recently developed
techniques to generate human induced pluripotent stem
cells (iPSCs) [1] allow the investigation of cells derived
from patients. This technological development has led to
the need to confirm functionality of the newly generated
neurons with respect to electrophysiological properties of
individual neurons, their ability to express pathophysio-
logically relevant phenotypes, and their capability to func-
tionally integrate into the brain’s circuitry. Despite the* Correspondence: oa1@columbia.edu
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article, unless otherwise stated.attractive possibility of studying newly generated human
neurons, previous studies have revealed problems regard-
ing the maturation of the stem cell-derived neurons, as
well as the survival of implanted iPSC-derived cells, the di-
rected differentiation into certain cell types [2] and the
tumorigenic potential of incompletely differentiated iPSCs
[2, 3]. Such limitations will have to be overcome before
newly generated human neurons become clinically useful.
In this review, we will first discuss the characteristics of
the development of both basic electrophysiological prop-
erties in maturing neurons and their synaptic activity, as
well as integration of individual neurons into synaptic cir-
cuitry. The passive and active membrane properties and
the presence of spontaneous postsynaptic currents are
strong indicators of neuronal maturation and can be used
to evaluate the potential therapeutic viability of the differ-
ent protocols. Next, we will evaluate the derangement of
synaptic properties underlying disease processes. Finally,
we will discuss recent studies on stem cell-derived human
neurons and how they recapitulate physiopathological
features of brain neurons.
The physiological role of synaptic
neurotransmission
Electrophysiological markers of neuronal development
and stem cell conversion
A central characteristic of neurons is their ability to send
and receive signals by means of action potential (AP)ed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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neurotransmission. The underlying neuronal properties
permitting intercellular signaling are progressively chan-
ging during early network formation as well as during
differentiation of stem cells into neurons. Indeed, the de-
velopmental stage of neurons can be assessed electro-
physiologically by measuring their passive and active
membrane properties as well as synaptic currents. Pas-
sive membrane properties commonly investigated in
studies monitoring neuronal development include input
resistance (Rin), membrane capacitance (Cm), and the
membrane time constant (τ) as well as the resting mem-
brane potential (RMP). With progressive neuronal devel-
opment, Rin and τ values have been found to decrease
whereas Cm values increase and the RMP shows a nega-
tive shift [4, 5]. These passive membrane properties ren-
der immature neurons highly excitable, as high Rin and τ
values together with depolarized RMPs enable AP gener-
ation in response to weak membrane currents. Thereby,
the electrophysiological profile of immature neurons
might function to compensate for the rather low fre-
quencies of synaptic neurotransmission in early develop-
ing networks by increasing the chance of AP generation
upon presynaptic transmitter release. Similar to passive
membrane properties, measurement of active membrane
properties underlying AP formation and propagation allows
for analysis of the electrophysiological profile of developing
neurons and is particularly helpful in distinguishing pyram-
idal glutamatergic from inhibitory interneurons via their
distinct AP shapes and firing patterns [6].
Synaptic activity is another fundamental feature that
characterizes neurons. The activity in early developing
networks differs from that of mature networks by a
number of factors, including the excitatory–inhibitory
shift of γ-aminobutyric acid (GABA), the occurrence of
giant depolarizing potentials (GDPs) and progressively
increasing frequencies of both GABAergic and glutamater-
gic spontaneous neurotransmission, indicative of develop-
mental synaptogenesis [7]. Importantly, spontaneous
synaptic activity after birth serves as a guidance signal
for synaptogenesis in immature neurons (reviewed in
[8]). Although the progression of synaptic neurotrans-
mission over the course of iPSC-derived neuron differ-
entiation has been described recently [9, 10], the
excitatory–inhibitory shift of GABA and the importance
of GDPs have yet to be investigated in detail. Thus, it is
currently unknown whether neuronal differentiation from
somatic cells shares the electrophysiological characteristics
of natural neuronal development.
Both in the developing and the adult central nervous
system, glial cells facilitate differentiation and matur-
ation of cells into neurons [11] and play fundamental
roles in synaptic development, homeostasis and activity
[12]. Astrocytes promote developmental synaptogenesisvia the release of thrombospondins, hevin and secreted
protein acidic and rich in cysteine [13, 14]. The expression
of thrombospondins coincides with the early postnatal
period of synaptogenesis while hevin and secreted protein
acidic and rich in cysteine are also expressed in astrocytes
in the adult central nervous system [15, 16]. In their role
of regulating the synaptic development and maintenance,
the astrocytes act by releasing glutamate or ATP [17, 18]
and cell contact molecules such as ephrins [19,20]. Con-
sistently, co-cultures of neural progenitor cells (NPCs) de-
rived from human iPSCs together with astrocytes show
significantly faster rates of neuronal maturation [10]. Add-
itionally, microglial cells, in coordination with the comple-
ment system, are involved in synapse degradation, termed
synaptic pruning [21–23]. Although several studies util-
izing iPSC-derived neurons used glial-conditioned
medium obtained from astrocyte-rich cultures, the lack
of microglial cells in iPSC-derived neuronal cultures
might negatively impact synaptic development in such
cells. Additionally, since microglia cells require comple-
ment system activation to exert their function on synaptic
pruning, the addition of complement system proteins
might be required.
Synaptic plasticity and its molecular machinery
Strong, repetitive synaptic activity leads to synaptic plasti-
city. Long-term potentiation (LTP) and long-term depres-
sion (LTD) are two forms of synaptic plasticity that have
been widely investigated and are linked to learning and
memory (reviewed in [24]). During induction of LTP at
the CA3–CA1 hippocampal synapse, large amounts of
glutamate are released from the presynaptic terminal and
bind to the N-methyl-D-aspartate receptors (NMDARs)
and the α-amino-3-hydroxy-5-methyl-4-isoxazolepropio-
nic acid receptors located at the postsynaptic membrane.
While during the resting state NMDARs are blocked by
Mg2+ ions, when a strong depolarization is induced by
glutamate binding to α-amino-3-hydroxy-5-methyl-4-iso-
xazolepropionic acid receptors the Mg2+ block is removed
and Ca2+ ions enter the cell via NMDARs. The calcium in-
flux activates a cascade of second messenger events that
trigger nuclear transcription factors followed by gene tran-
scription, protein synthesis underlying synaptic strength-
ening. NMDAR-dependent LTP thus requires presynaptic
glutamate release and postsynaptic depolarization promot-
ing structural presynaptic and postsynaptic changes [25].
Conversely, LTD can be induced by low-frequency stimu-
lation of presynaptic terminals, minimizing postsynaptic
calcium influx through NMDARs and the preceding
depolarization. Low levels of NMDAR activation promote
long-lasting decreases in synaptic efficacy. Importantly,
LTD might involve endocytosis of synaptic α-amino-3-hy-
droxy-5-methyl-4-isoxazolepropionic acid receptors and
reduction of dendritic spine surfaces [26].
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potentiation or depression are the intensity of presynap-
tic activation, postsynaptic depolarization and the
amount of calcium flowing through the NMDARs [27].
Because of the relevance of LTP and LTD in memory
formation, complete neuronal maturation includes the
formation of synapses capable of undergoing synaptic
plasticity. Currently, there have been no studies report-
ing functional synaptic plasticity in iPSC-derived or dir-
ect conversion-derived neurons. Obtaining neurons
capable of undergoing synaptic plasticity will probably
constitute one of the most challenging tasks in the field
of stem cell research.
Methods to analyze neuronal properties in vitro and
in vivo
In order to investigate the functionality of the neurons, dif-
ferent methodologies have been developed over the years.
The method of choice depends on many factors: the level
of resolution needed, the possibility to study neuronal cir-
cuitry or intact systems, the necessity to manipulate the ex-
perimental conditions, the interest in studying synaptic
events or sensory responses and, no less important, the
cost, time and difficulty of using the technique. Most of
the time, complete understanding of a phenomenon re-
quires the use of more than one methodology. In this
chapter, we present the methods most frequently used by
neuroscientists to analyze neuronal properties. A summary
of the characteristics of the methods described in this sec-
tion is presented in Table 1.
Electrophysiology
Electrophysiological properties of neurons in vitro and
in vivo can be studied by a series of techniques including
both intracellular and extracellular recordings, as well as
imaging techniques allowing investigation of neurotrans-
mitter release. The method of choice depends on the re-
quired level of detail and the specific scientific question
to be answered. At a cellular level, intracellular record-
ings are used to measure voltages or currents across the
cell membrane [28]. The patch clamp technique [29] al-
lows the study of single or multiple ion channels (ex-
cised patch technique), or of the electrical properties of
an entire cell (whole cell patch and perforated patch).
The use of patch clamp in cell cultures enables the
characterization of basic electrophysiological properties
of cells under both physiological and pathological condi-
tions and the investigation of synaptic neurotransmis-
sion. In contrast, patch clamp in brain slices enables the
investigation of semi-conserved neuronal circuits, and
the measurement of neurotransmission in specific areas
of the brain.
At a multicellular level, extracellular recordings of
local field potentials are used to study the collectiveactivity of many cells by monitoring the signals in the
extracellular space of the brain, in order to investigate
the synaptic connectivity of neuronal circuits in specific
areas. More recently, in vitro multi-electrode array
methods have been developed [30] and are currently
used in cell cultures or acute brain slices, with the ad-
vantage of having a high spatial and temporal resolution
of signals across a neuronal network. In addition, the
multi-electrode array technique can be combined with
intracellular recordings [31].
Another important category of electrophysiological
analysis is represented by in vivo recordings, where the
same techniques explained above are used in live ani-
mals. With this method, one can study brain regions or
neurons in their intact state with their normal comple-
ment of inputs and targets. The cells being studied usu-
ally have not been severed or damaged, in contrast to
studies in brain slices, and have developed normally in
the intact organism, in contrast to the culture prepar-
ation. Importantly, this technique allows for the investi-
gation of neuronal responses to sensory stimuli.
Calcium imaging
Calcium is an essential intracellular messenger in mam-
malian neurons. At rest, most neurons have an intracel-
lular calcium concentration of about 50 to 100 nM that
can rise transiently during electrical activity to levels that
are 10 to 100 times higher [32]. Use of the calcium im-
aging technique to investigate calcium variations in liv-
ing cells and animals is thus fundamental. In presynaptic
terminals, Ca2+ influx triggers exocytosis of synaptic ves-
icles containing neurotransmitters [33]. Postsynaptically,
a transient rise of the Ca2+ level in dendritic spines is es-
sential for the induction of activity-dependent synaptic
plasticity [34].
Briefly, the calcium imaging technique consists of two
steps: loading the cells with fluorescent molecules that can
respond to the binding of Ca2+ ions by changing their
fluorescence properties, and detecting Ca2+ transients
using a fluorescence microscope and a charge-coupled de-
vice camera. Images are then analyzed by measuring fluor-
escence intensity changes, and the derived fluorescence
intensities are plotted against calibrated values for known
calcium levels to learn the Ca2+ concentration.
There are two main classes of calcium indicators: chem-
ical indicators and protein-based genetically encoded cal-
cium indicators. Among the chemical indicators, the most
recently developed Oregon Green BAPTA and fluo-4 dye
families [35] are widely used in neuroscience because they
are relatively easy to implement and provide large signal-
to-noise ratios. Genetically encoded calcium indicators do
not need to be loaded onto cells, but instead the genes en-
coding for these proteins can be transfected into cell lines
[36]. To detect the fluorescence changes with high spatial
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takes advantage of the development of new imaging in-
strumentation. A major advance in the early 1990s was
the introduction of two-photon microscopy by Denk and
colleagues [37] and its use for calcium imaging in the ner-
vous system [38]. In a recent study, the group of Deisseroth
developed a technique, termed fiber photometry, to meas-
ure Ca2+ signals in neuronal processes in vivo using the
genetically encoded calcium indicator GCaMP [39]. This
method might also be useful to monitor neuronal activity
of in vitro differentiated neurons following transplantation
in future studies.
Optogenetics
Recently, a new technology has been developed to con-
trol, either by exciting or inhibiting, the activity of tar-
geted individual neurons: optogenetics. An August 2005
report described how neurons became precisely respon-
sive to light upon introduction of a microbial opsin gene
[40]. In the following years, several additional reports
demonstrated that some microorganisms known for be-
ing able to produce visible light-gated proteins that dir-
ectly regulate the flow of ions across the plasma
membrane (channelrhodopsin, bacteriorhodopsin and
halorhodopsin) are capable of turning neurons on or off,
rapidly and safely, in response to diverse colors of light
[41–43]. This innovative approach allows neuroscientists
to control defined events in defined neuronal types and
projections at defined times in intact systems, while
maintaining high temporal (AP scale) precision. An im-
portant application of optogenetics is represented by its
use for studying well-defined biochemical events within
behaving mammals [44–46]. The potential of optoge-
netics selectively activating specific neuronal subtypes
has also been applied to study pathological processes.
Gradinaru and colleagues used optogenetics to systemat-
ically drive or inhibit an array of distinct circuit elements
in freely moving parkinsonian rodents and found that
therapeutic effects within the subthalamic nucleus can
be accounted for by direct selective stimulation of affer-
ent axons projecting to this region [47].
Importantly, optogenetic approaches have been used
to confirm functional integration into pre-existing net-
works of neurons and NPCs differentiated from iPSCs
and embryonic stem cells (ESCs) [48–52]. By selectively
expressing channel rhodopsin in iPSC-derived or ESC-
derived neurons, functional synaptogenesis can be con-
firmed by measuring postsynaptic responses triggered by
light-stimulation in co-cultured mouse neurons as well as
in mouse brain slices following stereotaxic injection of
in vitro differentiated cells. Furthermore, a recent study
transplanted ESC-derived motor neurons that formed
functional neuromuscular connections allowing for opto-
genetic control of muscle contraction in vivo [51]. The useof optogenetic technologies in combination with in vitro
differentiation methods thus provides an attractive pro-
spect for future patient-specific treatments.
Vesicle cycling
Neurotransmitter release is often investigated though
FM dye visualization during vesicle cycling [16]. These
dyes are fluorescent molecules used to monitor the
movement of synaptic vesicles. Their use is based on
their amphipathic properties. Dyes can be reversibly
endocytosed and exocytosed via lipid membrane bud-
ding and fusion, but dyes themselves cannot permeate
the membrane. To image presynaptic function, FM dyes
are taken up into synaptic vesicles in an activity-
dependent manner, termed loading. After washout and
subsequent chemical/electrical stimulation, dyes are re-
leased from presynaptic boutons, termed unloading.
The loss in fluorescence intensity during loading and
unloading steps thus provides information about pheno-
types and rates of presynaptic neurotransmission [53].
Clinical investigation of neuronal function
The study of neuronal electrophysiological properties in
a clinical setting has been mostly permitted by electro-
encephalography (EEG) and evoked potentials. Now-
adays, the combination of scalp EEG recording with
functional magnetic resonance imaging (fMRI) allows an
in-depth understanding of phenomena underlying EEG
activity. By combining the two techniques, one can de-
termine which brain areas change their neuronal activity
during an epileptic discharge, and consequently under-
stand the anatomical location and physiological activa-
tion of neuronal networks generating normal and
abnormal EEG signals. For instance, in temporal lobe
epilepsy, temporal localized spiking on EEG has been
found to be accompanied by a widespread activation in
distant regions on fMRI, especially in the contralateral
homologous regions, suggesting that the neuronal net-
work involved in temporal spiking is much wider than
what appears on scalp EEG [54]. Furthermore, in idio-
pathic generalized epilepsies, the bilateral and synchron-
ous spike and wave pattern on EEG is accompanied on
fMRI by activation in the thalamus and by widespread,
bilateral and symmetrical deactivation in the cortex.
Nowadays, clinical investigation also uses techniques
that have been developed especially for animal studies.
For instance, at the level of single neurons, epileptic ac-
tivity is investigated on brain specimens resected during
epilepsy surgery using the patch clamp technique. These
studies have shown a major role for ion channels in the
generation of excessive and hypersynchronous neuronal
discharges (the so-called paroxysmal depolarizing shifts),
a hallmark of the epileptic activity. In fact, the above-
mentioned discharges originate from alterations of
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by spontaneous or experimental modifications of the
properties of voltage-dependent or receptor-activated
ion channels [55].
Integration of stem cell-derived neurons is not yet
used in clinical practice. However, implants of iPSC-
derived neuronal precursor cells in embryonic or adult
mouse brains are currently explored. Thus, one can en-
vision a time at which EEG, fMRI and evoked potentials
will be utilized to assess functionality of stem cell-
derived neuronal grafts in humans.
Synaptic dysfunction in neurological diseases
On the abnormality of neuronal circuits in neurological
diseases
Dysfunctional synaptic circuits have been found in neu-
rodevelopmental disorders such as autism spectrum
disorders, psychiatric disorders such as schizophrenia,
and neurodegenerative disorders including Alzheimer’s
disease (AD), Parkinson’s disease (PD) and spinal mus-
cular atrophy (SMA) [56–66]. Both hyperconnectivity
within local and short-distance frontal cortical connect-
ivity, and hypoconnectivity between frontal lobe and
temporal lobe multimodal association cortices have
been described in autism spectrum disorder human
brain [56]. In schizophrenia patients, massive gray mat-
ter loss results in the reduction of spine density in the
superior temporal gyrus associated with auditory hallu-
cinations [57]. In addition, a mouse model of NMDAR
hypofunction can reproduce the hippocampal deficits
and cognitive abnormalities that have been observed in
schizophrenia patients [58].
In AD amyloid precursor protein transgenic mice
there is a reduction of sodium current density, which
results in aberrant EEG activity and impaired perform-
ance with the Morris water maze memory test [59].
Electroencephalographic recordings in human amyloid
precursor protein transgenic mice revealed a network
hypersynchrony caused by decreased levels of the
interneuron-specific and parvalbumin cell-predominant
voltage-gated sodium channel subunit Nav1.1 [60]. Ab-
errant increases in network excitability and compensa-
tory inhibitory mechanisms may contribute to amyloid
beta-induced neurological deficits in human amyloid
precursor protein mice and, possibly, also in humans
with AD [61, 62]. Massive destruction of the dopamin-
ergic nigrostriatal circuit entails motor and cognitive
complications in PD patients [63]. Mutant huntingtin
expression in Huntington’s mouse model changes stri-
atal excitatory synaptic activity by decreasing glutamate
uptake and increasing signaling at NMDAR [64]. In
Sod1 transgenic mice, an amyotrophic lateral sclerosis
model, motor neurons become hyperexcitable. Dimin-
ished control of motor neuron firing has been explainedby the loss of presynaptic motor axon input on Renshaw
cells occurring in the early stages of amytrophic lateral
sclerosis and the disconnection of the recurrent inhibitory
circuit [65]. In a Drosophila model of SMA, chronic dys-
function of the sensory-motor circuit causes functional
impairments such as muscle weakness and progressive
motor neurodegeneration [66]. Taken together, observa-
tions from these models and patients might inspire studies
using human iPSC-derived models.
Role of proteins related to neurodegenerative diseases in
alterations of synaptic properties and learning
and memory
One of the most common features of neurodegenerative
diseases is the progressive and region-specific accumula-
tion of proteins. These aggregated proteins induce neu-
rons in the affected regions to adapt to their immediate
environment and affect synaptic plasticity [67]. For in-
stance, two proteins are involved in AD: amyloid beta,
which is deposited in extracellular amyloid plaques; and
tau, forming intracellular neurofibrillary tangles. Amyl-
oid beta inhibits NMDAR-dependent LTP and promotes
LTD in the hippocampus. Additionally, dysregulation of
LTD is associated with GSK-3β, an enzyme responsible
for hyperphosphorylation of tau [68].
With respect to PD, cortical Lewy bodies are found in
the soma of nigral dopamine neurons. These Lewy bod-
ies are composed of protofibrils of aggregated α-
synuclein [69]. In animal models overexpressing mutated
forms of α-synuclein, dopaminergic neurotransmission is
impaired, leading to loss of dopaminergic neurons and
the impairment of LTD in medium spiny striatal neurons
and ultimately to cognitive and motor deficits.
With regard to SMA, a deficiency of survival motor
neuron protein is associated with sensory-motor net-
work dysfunction and muscle deterioration. Importantly,
in mice lacking survival motor neuron protein a reduc-
tion of proprioceptive synaptic inputs onto motor neu-
rons and spinal reflex deficits have been observed [70].
Nevertheless, animal models cannot fully recapitulate
the key aspects of human models [71]. Regarding tauo-
pathy, the human adult central nervous system can ex-
press six different tau isoforms whereas only tau-4R is
expressed in mice adult neurons. Additionally, an im-
portant concern is the failure of patient-specific donor
cells to maintain age-associated markers in late-onset
human iPSC-based disease models. Expression of pro-
gerin, a truncated form of lamin A involved in Hutchin-
son–Gilford progeria syndrome, has been studied as a
strategy for reintroducing age-like features such as age-
related markers in iPSC fibroblasts and robust degen-
erative phenotypes [72, 73]. Thus, it would be interest-
ing to test whether low levels of progerin could
facilitate iPSC maturation [74].
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have found from stem cell research
Physiological neuronal development: analysis of
neural markers
Neuronal differentiation of stem cells is commonly
monitored through immunocytochemical methods con-
firming the expression of specific neuronal markers [1].
For instance, human iPSCs commonly express pluripo-
tent markers including human embryonic stem cell sur-
face antigens SSEA3 and SSEA4, tumor-related antigens
TRA-1-60, TRA-1-81 and TRA-2-49/6E, and NANOG
protein. Undifferentiated pluripotent stem cell marker
genes OCT3/4 and SOX2 are also detected by RT-PCR.
The conversion of reprogrammed iPSCs into neuronal
cells can be confirmed using the neuroectodermal
marker nestin, the neuronal lineage marker Pax6, the
neuronal differentiation marker T-box brain 1, and
layer-specific markers for developing cortical cells in-
cluding upper layer (cut-like homeobox 1) and deeper
layer projection neuron markers (COUP-TF-interacting
protein 2) [75]. Similar neuronal markers can also be
observed in pyramidal neurons derived from ESCs [76].
Regional identity is, in turn, specified through Forkhead
box G1 and Orthodenticle homeobox 2 for the dorsal
forebrain region, whereas distal-less homeobox 2 is a
marker for developing ventral forebrain identity in re-
programmed and embryonic-derived neurons [77, 78].
Mature reprogrammed neurons can be identified through
microtubule-associated protein MAP2 expression [79]. In
addition, neuorotransmitter-related markers are used to
indicate fully developed reprogrammed forebrain neurons.
Markers for glutamatergic neurons include the vesicular
glutamate transporter VGLUT1 and phosphate-activated
glutaminase. Glutamate decarboxylase is a commonly
used marker to identify GABAergic neurons differentiated
from human iPSCs [80]. Immunocytochemical markers
have also been used to investigate synapse formation in
iPSC-derived neurons. Among these markers are synapto-
physin and synapsin I on the presynaptic side and postsyn-
aptic density protein PSD95 as well as Homer1 at the
postsynaptic level [75].
Relying on immunocytochemical methods alone to
identify synaptic connections might have significant pit-
falls. Postsynaptic receptors have been shown without
corresponding markers for the presynaptic active zone
[81]. Similarly, presynaptic clusters without correspond-
ing postsynaptic proteins have been identified [82]. In
other studies, areas with both presynaptic and postsyn-
aptic proteins have revealed no functional synapses
[83]. On the other hand, it has been demonstrated that
synapsin I might not always be present in functional
synapses [84]. Furthermore, nonspecific antibody stain-
ing might yield spurious results [85]. Thus, it has been
suggested that industrial antibody producers should bemotivated to test their products more rigorously before
making them commercially available to the scientific
community [86].
Various studies characterized the presynaptic expres-
sion of neurotransmitters as well as the postsynaptic
expression of the respective neurotransmitter receptors,
such as glutamate receptors and GABA receptors
[78, 87–90]. However, prominent expression of such
markers was not always reflected in equally prominent
and mature synaptic neurotransmission. In the study by
Vazin and colleagues, iPSC-derived cortical neurons
readily expressed high levels of GABA and glutamate,
but electrophysiological investigation showed highly im-
mature synaptic currents at low frequency and devoid of
typical neurotransmission-derived current kinetics [78].
Correspondingly, the study by Marchetto and colleagues
reported altered spontaneous neurotransmission in iPSC-
derived neurons of Rett syndrome patients compared with
wild type but did not find alterations in the immunohisto-
chemical analysis of synaptic markers [87]. In contrast, a
study on iPSC-derived neurons of trisomy 21 patients
found a reduction in spontaneous neurotransmission fre-
quency and reduced synapsin I staining [90]. In iPSC-
derived neurons of schizophrenia patients, various pre-
synaptic and postsynaptic markers appeared to be aber-
rantly expressed, but measured neuronal connectivity
remained unaffected [88, 91]. Similarly, in a study of spon-
taneous movement disorder patient-derived neurons, re-
ductions in synaptic neurotransmission frequency and
amplitude correlated with reduced glutamate receptor and
synapsin I expression. The localization of synaptic proteins
alone is thus insufficient and the use of electrophysiological
methods is necessary to confirm the presence of functional
synapses or pathophysiologically related alterations.
Recent iPSC studies are using additional approaches,
such as microarray analysis, deep RNA sequencing, and
quantitative PCR arrays, to determine the status of neur-
onal differentiation [92]. Microarray analysis offers a
customized array containing genes specific to particular
cell populations or signaling pathways. This method can
assess characteristic features of the pluripotent state and
stem cell differentiation. Deep RNA sequencing provides
high sensitivity to detect low-copy transcripts, long non-
coding RNAs, novel transcripts, and splice isoforms which
are seen during the transition from pluripotent stem cells
to early differentiated neurons [93]. Using a quantitative
PCR array, the expression of key pluripotency-associated
genes in the iPSC differentiation can be quantified and the
dynamic of interested gene expression can be tracked [94].
Nevertheless, it should be pointed out here that the pres-
ence of neural markers alone is insufficient to confirm full
neuronal functionality [9]. Thus, analysis of electrophysio-
logical parameters is to be performed when studying
in vitro differentiated neurons.
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of induced pluripotent stem cell-derived and directly
converted neurons
Terminally differentiated cells can be converted into
neurons either by first generating iPSCs [1] and subsequent
neuronal differentiation [9, 87, 95, 96] or by direct neuronal
conversion using viral transduction of specific factors to
produce induced neuronal (iN) cells [97–101]. These
methods allow for the generation of a range of neuronal cell
types, including dopaminergic neurons [100], motor neu-
rons [96], cortical neurons [102] and sensory neurons
[103]. Both methods of neuronal differentiation produce
glutamatergic pyramidal neurons [9, 99, 101, 104] as well as
GABAergic interneurons [105, 106]. In many of these stud-
ies, electrophysiological methods were used to investigate
the functional quality of generated neuronal cells.
Electrophysiological development in vivo
In the past three decades, the development of electro-
physiological properties in vivo has been well characterized
in rodent neurons of various brain structures [5, 107–110].
It was found that neurons in early neonatal development
are characterized by Rin values higher than 1 GΩ, with a
rapid decline over the course of the first postnatal month
to around 100 MΩ. Similarly, τ values are usually high (>30
milliseconds) around the perinatal period, indicating slow
adaptation of the membrane potential to membrane cur-
rents. τ values also decrease rapidly in the first postnatal
month to around 10 to 20 milliseconds. Cm values have
been shown to be below 50 pF at the time of birth and pro-
gressively increase over the first 2 weeks after birth. Con-
sistently, APs of perinatal rodent neurons are characterized
by small amplitudes of 30 to 40 mV, broad full widths at
half-maximum (FWHMs) of more than 3 milliseconds and
depolarized threshold potentials of around −30 mV. Similar
to passive membrane properties, AP properties mature
equally rapid over the first postnatal month, with AP ampli-
tudes increasing to >90 mV, FWHMs becoming faster than
1.5 milliseconds and AP thresholds reaching more hyper-
polarized values at around −40 mV, depending on the spe-
cific brain area and cell type. In addition to intrinsic
electrophysiological properties, the development of synaptic
neurotransmission has been equally well described in vari-
ous studies using developing rodent neurons. It was shown
that neurotransmission events occur already in the im-
mediate neonatal period at low frequency (<0.5 Hz) and
that the frequency of spontaneous neurotransmission
increases progressively with development [111, 112]. An
indication for physiological network formation is the
occurrence of GDPs, which are network-wide bursts of
synaptic activity during the first postnatal week in ro-
dents [7]. GDPs are associated with excitatory actions of
GABA and thus occur in early neuronal development
prior to the excitatory–inhibitory shift.In contrast to rodents, there are only a few studies on
the development of electrophysiological properties in
primate neurons. The stage of rodent brain development
is thought to be equivalent to the developmental stage of
the human brain around the time of the third trimester
of pregnancy [113]. Consistently, a study in nonhuman
primates found that neurons at the time of birth present
electrophysiological and synaptic properties that are al-
most fully matured [114]. Thus, although the level of
neuronal maturity at the time of birth is different be-
tween rodents and primates, including humans, it is
likely that neurophysiological properties develop in a
similar manner across different species, although with
different time courses.
Electrophysiological development of induced pluripotent
stem cell-derived neurons
Neurons derived from either rodent or human iPSCs
have been shown to fire a single AP in response to de-
polarizing current injections as early as 3 weeks after dif-
ferentiation, and the number of generated APs rises with
increased culture durations [9, 10, 106]. Table 2 presents
an overview of recent electrophysiological characteriza-
tions of human iPSC-derived neurons. Interestingly, one
study reported sodium currents in iPSC-derived neurons
1 week after differentiation, a time point at which AP fir-
ing was not yet observed [106], indicating that the pres-
ence of sodium currents alone does not implicate a cell’s
ability to fire APs. In two studies on human iPSC-
derived neurons, APs show amplitudes around 30 mV
and FWHMs around 8 milliseconds 1 month after differ-
entiation [9, 10]. After 2 months, AP properties matured
significantly, showing AP amplitudes of 50 mV and
FWHMs of 4 to 6 milliseconds. In the same studies, Rin
values matured similarly from 1 to 3 GΩ 1 month after
differentiation to 0.5 to 1 GΩ after 2 months. Other pas-
sive membrane properties followed the same path. Thus,
passive membrane properties experienced similar develop-
mental shifts as AP properties. Importantly, electrophysio-
logical properties matured faster in human iPSC-derived
neurons co-cultured with astrocytes, showing Rin values
below 1 GΩ after 2 months [10].
The formation of synaptic connections is of central
importance in the estimation of functional quality of
in vitro differentiated neurons. Electrophysiologically,
the measurement of spontaneous neurotransmission
provides information about the network. In neurons de-
rived from human iPSCs, spontaneous neurotransmis-
sion occurs between 3 and 6 weeks after differentiation
[9, 10, 104] and requires co-culturing of iPSC-derived
neurons with mouse glial cells. When cultured in glia
conditioned medium, AP-independent miniature neuro-
transmission occurs at low frequency in 11 % of cells
1 month after differentiation of human iPSCs [9]. When
Table 2 Summary of key studies on electrophysiological profiles of human iPSC-derived neurons
Pre and colleagues, 2014 [9] Tang and colleagues, 2013 [10] Zhang and colleagues, 2013 [120]







Cell line 7889O WT126, WT33 Not stated
DIV 31 to 38 41 to 45 55 55 42 60 42 60 21
AP firing (% of cells) 20 48 60 86 NQ NQ NQ NQ >95
Single (%) NQ NQ NQ NQ NQ NQ NQ NQ NQ
Repetitive (%) NQ NQ NQ NQ 16 73 NQ
Spontaneous AP (%) NQ NQ NQ NQ NQ NQ NQ NQ NQ
n 18 27 20 15 25 NQ 22 NQ 33 to 34
Rin (MΩ) 2,500.0 2,200.0 1,700.0 NQ NQ 695.0 NQ 302.0 NQ
Cm (pF) NQ NQ NQ NQ NQ 27.0 NQ 119.0 NQ
τ (milliseconds) 34.0 29.0 21.0 NQ NQ NQ NQ NQ NQ
RMP (mV) −35.0 −38.0 −49.0 NQ NQ −44.0 NQ −59.0 NQ
n 89 75 103 NQ NQ 22 NQ 23 NQ
Spontaneous activity (%) 11 16 21 27 NQ NQ NQ NQ >95
Evoked potential (%) NQ NQ NQ NQ NQ NQ NQ NQ >95
n 8 6 20 15 NQ NQ NQ NQ 33 to 34
Co-culture x Mouse glial cells x x Mouse astrocytes Mouse astrocytes Mouse glial cells
AP, action potential; Cm, membrane capacitance; DIV, days in vitro; iN, induced neuronal; iPSC, induced pluripotent stem cell; NPC, neural progenitor cell; NQ, not quantified; Rin, input resistance; RMP, resting
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neurotransmission is first observed 2 weeks after differ-
entiation followed by continuous increases in frequency
and amplitude over the course of 60 days [10]. However,
data on miniature neurotransmission were not de-
scribed by Tang and colleagues [10]. Importantly, GDP-
like neurotransmission bursts have been reported in
two studies on cultured neurons derived from human
iPSCs [10, 104]. Whether human iPSC-derived neurons
exhibit excitatory GABAergic neurotransmission associ-
ated with the GDP phenomenon remains unclear.
There are limited electrophysiological data available
on the maturation of iPSC-derived neurons in vivo and
transplantation of human ESC-derived and iPSC-derived
neurons into rodent brains has been performed in few
studies [76, 115, 116]. Human ESC-derived neurons
showed mature electrophysiological properties and func-
tional integration into the developing rodent brain, as
indicated by high rates of repetitive AP firing and high
frequencies of synaptic neurotransmission [76, 115].
Similarly, iPSC-derived neurons were also shown to inte-
grate into the rodent brain and form functional synapses
[116]. Nevertheless, only 1 % of cells survived in the
mouse brain after 7 months in the study by Nicholas
and colleagues [115] and passive and active membrane
properties were not characterized in detail in any of
these studies. Further investigation of in vivo maturation
of iPSC-derived neurons is thus required.
Electrophysiological development of directly converted
neurons
The neurophysiological development of the direct con-
version of mouse-derived or neonatal human-derived
somatic cells appears to follow a similar path to iPSC-
derived neurons, with reports of AP firing cells as early
as 8 days after transduction [99, 101, 105, 117]. However,
when transducing somatic cells from adult human tissue,
up to 8 weeks are required to obtain neuronal cells cap-
able of AP generation and the number of cells that fire
multiple APs remains low [97, 101, 108]. Table 3 pre-
sents an overview of recent electrophysiological charac-
terizations of human induced neurons. In the limited
number of adult human iN cells capable of firing APs,
the AP properties were shown to be highly variable, with
broad FWHMs (>6 milliseconds), and most cells only
fired single APs [108]. Importantly, it appears that hu-
man iN cells derived from adult somatic cells are not vi-
able for long periods of time [118], making it difficult to
culture human iN neuronal cells to functional maturity.
Passive membrane properties of iN cells derived from
adult human tissues have often only been reported
superficially [97, 118]. However, a recent study reported
Rin values of human iN cells in the GΩ range, Cm values
around −30 pF and an RMP of −40 mV 1 month aftertransfection, reflecting incomplete neuronal develop-
ment [108]. Importantly, studies applying direct neur-
onal conversion to both neonatal and adult human
somatic cells demonstrated clearly that passive mem-
brane properties of iN cells derived from adult human
tissue remain highly immature at time points at which
iN cells derived from neonatal human tissue have
already matured significantly [97, 99, 101, 119]. Current
iN methods thus appear to be rather inefficient when
applied to adult human fibroblasts.
Spontaneous neurotransmission has been reported for
iN cells derived from direct neuronal conversion of
mouse and fetal human somatic cells [99, 117]. However,
directly converted iN cells require co-culturing with ma-
ture neurons in order to display spontaneous neuro-
transmission. Thus, it remains unclear whether iN cells
alone would be capable of functional synapse formation.
Although several studies report the occurrence of neuro-
transmission in iN cultures derived from adult human
cells [97, 118, 101], example traces showing spontaneous
neurotransmission might require more in-depth analysis.
One of these studies recorded spontaneous neurotrans-
mission in pure iN cultures [97] but the presented
neurotransmission events appear electrophysiologically
atypical, lacking fast rise and slow decay times. Further-
more, a recent study could not observe spontaneous or
evoked neurotransmission in human iN cultures [108].
Consistently, GDPs have been described in mouse and
fetal human fibroblast-derived iN cells [99, 117] while
no GDPs have been reported for iN cells derived from
adult human cells, even after transplantation into fetal
mouse brains [118].
Recently, a new approach has been developed to com-
bine direct conversion with ESC and iPSC methods,
termed ESC-iN and iPSC-iN [120]. In their study, Zhang
and colleagues converted NPCs derived from human
iPSCs to neurons via the transduction of Neurogenin-2.
These cells show very mature electrophysiological pro-
files, as indicated by high rates of repetitive AP firing
and high frequencies of spontaneous neurotransmission,
already after 3 weeks. Furthermore, the commonly ob-
served variability in the level of neuronal differentiation
of different iPSC lines could be prevented with this
single-step conversion method. Although no data on
passive membrane properties were presented, the dis-
played current and membrane potential traces appear
equivalent to those of fully mature neurons. The iPSC-
iN method might thus be the currently most efficient
way to differentiate human iPSCs to functional neurons.
Gene expression analyses of human induced pluripotent
stem cell-derived and induced neurons
Over the course of neuronal development, various genes
are time dependently expressed and can be analyzed to
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4 to 8 1.5 to 11 2 3 to 5 2 to 4 2 to 4 2 to 4 NQ 5 10 13 16 1 to 4 NQ NQ NQ NQ NQ
DIV 25 to 30 30 16 18 14 to 25 34 to 35 28 to 35 21 30 to 32 30 to 32 30 to 32 30 to 32 23 to 34 NQ NQ 35 to 56 35 to 56 21 to 28
AP firing
(% of cells)
81 12 NQ NQ 21 100 79 NQ 86 83 79 91 47 90 NQ 85 60 63
Single (%) NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ 62
Repetitive (%) 20 NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ 77 56 7
Spontaneous
AP (%)
15 NQ 81 NQ 2 0 3.0 NQ 29 0 NQ NQ NQ NQ NQ 10 NQ 0
n 29 25 16 8 42 5 29 NQ 7 6 14 12 60 10 NQ 27 15 27
Rin (MΩ) 405.0 1,067.0 1,100.0 NQ 1,770.0 1,110.0 1,500.0 x 157.0 152.0 966.0 843.0 x NQ NQ 2,600.0 2,800.0 1,060.0
Cm (pF) 30.5 35.9 10.6 NQ 16.0 25.1 23.0 x NQ NQ NQ NQ x NQ NQ 16.3 22.9 33.3
τ (milliseconds) NQ NQ NQ NQ NQ NQ NQ x NQ NQ NQ NQ x NQ NQ NQ NQ 35.4
RMP (mV) −45.0 x −41.8 NQ −52.1 −59.5 −41.0 x −45.3 −41.6 −62.4 −58.6 x −49.5 NQ −42.0 −31.4 −42.1
n 21 21 16 8 52 21 29 x 7 6 14 12 x 6 NQ 27 15 27
Spontaneous
activity (%)
25 43 x x 0 19 33 x x x x x x x x 71 84 0
Evoked
potential (%)
x x x x 0 14 0 x x x x x x x x 45 47 0
n 8 7 x x 20 21 6 x x x x x x x x 12 to 14 10 to
12
9 to 57
Co-culture x x x x Mouse
cortical
neurons
x x x x x x x x Mouse
glial cells
x
Note the more immature electrophysiological properties of neurons converted from adult somatic cells compared with those converted from fetal or neonatal tissues. AP, action potential; BAM, Brn2, Ascl1, Myt1l;
DAM, NeuroD2, Ascl1, Myt1l; Cm, membrane capacitance; DIV, days in vitro; five factors, Lhx3, Hb9, Isl1, Ngn2, NeuroD1; four factors, Lhx3, Hb9, Isl1, Ngn2; hiN, human induced neuronal; miN, mouse induced neuronal;
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early neuronal lineage determination of ESCs, NPCs ex-
press nestin [121]. During embryonic brain development
in humans, neuronal precursor cells migrate to their tar-
get brain regions around the eighth gestational week,
where they subsequently express layer-specific markers
and develop into functional neurons [122, 123]. Analysis
of such region-specific and cell type-specific gene ex-
pression thus enables the identification of neuronal sub-
types and their developmental stage resulting from
in vitro differentiation. Several studies have investigated
the extent of neuronal differentiation of human iPSCs
using whole genome analysis [75, 115, 124]. Brennand
and colleagues compared the gene expression profile of
neurons differentiated from human iPSCs with that
available through the Allen Brain Atlas [124]. Interest-
ingly, they found that the gene expression profile was
most similar to human neurons around the age of the
first trimester of pregnancy [124]. The investigation by
Mariani and colleagues came to a similar conclusion: hu-
man iPSC-derived neurons showed gene expression pro-
files resembling those of human neurons at gestational
weeks 8 to 10 [75]. In the case of studies on directly
converted neurons, no similar analyses have been per-
formed. However, due to the general inferiority in elec-
trophysiological profiles of human iN cells compared
with iPSC-derived neurons, one would expect an equally
or even more immature gene expression profile.
Grafting neurons derived from human stem cells
Several studies have recently characterized the functional
properties of the neuronal cultures derived from human
stem cells. These studies have demonstrated that neu-
rons derived from mouse and human stem cells display
neuronal-like characteristics, including voltage-gated
currents and the ability to fire APs. However, the matur-
ation of human iPSC-derived neurons appears incom-
plete, as indicated by their immature passive and active
membrane properties [9]. Importantly, co-culturing hu-
man iPSC-derived neurons with mouse glial cells im-
proved neuronal maturation [9, 10]. In these two
studies, the electrophysiological properties of the iPSC-
derived neurons co-cultured with mouse glial cells were
compared with those of neurons grown on laminin-
coated substrates. Both groups showed an increase in
the number of cells capable of firing an AP in response
to a current step for neurons co-cultured with glial cells,
as well as increased spontaneous synaptic activity and a
more hyperpolarized resting membrane potential. While
the study by Tang and colleagues focused especially on
the morphology of the forming network, by showing an
increased complexity of dendritic arborization in neu-
rons co-cultured with glial cells [10], the article by Pre
and colleagues analyzed especially synaptic activity,demonstrating an increase in frequency and amplitude
of the spontaneous excitatory postsynaptic currents in
co-cultured neurons compared with neurons plated on
laminin [9]. In conclusion, while the two groups used dif-
ferent differentiation protocols and analyzed neurons at
different time points, both studies found enhanced neur-
onal maturation in cells co-cultured with mouse glia. Con-
sistent with this finding, maturation of fibroblast-derived
NPCs was enhanced when implanted into embryonic or
adult mouse brains [125]. This observation represents one
of the most promising future applications of stem cell re-
search: to produce grafts for neurological diseases.
Several studies have transplanted ESC-derived neurons
into animal models of neurological diseases. ESC-derived
neurons were found to be integrated within brain circuits
and to differentiate into mature neurons when implanted
into mouse embryos [126]. These neurons exhibited typical
neuronal membrane properties associated with postsynap-
tic currents following electrical stimulation. However,
spontaneous synaptic activity was not investigated in this
study. In another study, ESC-derived neurons were able to
integrate into brain slices [127]. Shortly after implantation
(1 to 3 weeks), passive and active membrane properties be-
came neuronal-like, indicating improved maturation com-
pared with in vitro studies [9, 10], and spontaneous
inhibitory/excitatory postsynaptic currents were present.
This trend was confirmed by another study, in which
iPSC-derived NPCs were implanted into embryonic mouse
brain [76].
With regard to the application of iPSCs for regenera-
tive medicine, the use of iPSCs may eliminate the
chances of immune rejection as patient-specific cells
may be used for transplantation [128]. There are two
main strategies for using iPSCs to treat neurological dis-
orders. The first is to produce new neurons to replace
those lost during disease progression. The second strat-
egy is to produce glial cells that could protect neurons
from ongoing degeneration by expressing and secreting
neuroprotective proteins, such as growth factors [129].
On the other hand, generating neuronal cells from
patient-derived tissues allows for the direct investigation
of cellular disease-related phenotypes and could lead to
the development of suitable treatment options (as
reviewed in [130–132]). Additionally, recapitulation of
the connectivity and circuitry dysfunction phenotypes in a
number of neurological disease-specific iPSCs have been
established (summarized in Table 4). Various studies could
identify dysfunctional connectivity in neurons generated
from patient tissue of various diseases, including AD,
amyotrophic lateral sclerosis, Dravet syndrome, Down
syndrome, Fragile X syndrome, PD, Phelan–McDermid
syndrome, Rett syndrome, SMA and schizophrenia
[78, 87–90, 96, 106, 133–145]. For example, the study by
Marchetto and colleagues found reduced frequencies of




Alzheimer’s disease Cortical neurons • Accumulated extracellular Aβ oligomers inside familial
and sporadic neurons, leading to oxidative stress
[78, 133–135]
• Selectively decreased glutamatergic neurons rather than GABAergic
neurons with increasing concentrations of the globulomeric form of Aβ42
• Redistributed hyperphosphorylated tau to the somatodendritic compartments
Amytrophic lateral sclerosis Motor neurons, astrocytes • Hyperexcitability of amytrophic lateral sclerosis patient-derived motor neurons [138, 139]
• Kv7 channel-activator retigabine could revert motor neuron hyperexcitability
• Astrocytes from amytrophic lateral sclerosis patient-derived iPSCs show
toxicity towards motor neurons in co-culture
Dravet syndrome Glutamatergic and
GABAergic neurons
• Impaired action potential generation in GABAergic neurons derived
from Dravet syndrome patient tissue
[106, 140, 141]
• Hyperexcitability and spontaneous epileptic action potential firing
in glutamatergic neurons
• Increased sodium currents
• Hyperexcitability was reduced after treatment with phenytoin
Down syndrome Cortical neurons • Defected the ability to form functional synapses in early trisomy
of chromosome 21 iPSC neurons
[90, 142]
• Diminished number of neural progenitor cells associated with a
proliferation deficit and increased apoptosis.
• Reduced number and length of neurites from soma of neurons
• Decreased frequencies of spontaneous neurotransmission,
affecting excitatory and inhibitory synapses equally
Fragile X syndrome NPCs, neurons of
unspecified subtype
• Impaired neuronal differentiation of Fragile X syndrome patient-derived iPSCs [143, 144]
• No clear effect on glial differentiation
• No activation of mutant FMR1 locus during iPSC generation from
Fragile X syndrome patient tissue
Parkinson’s disease Dopaminergic neurons • Reduced numbers of neurites and neurite arborization [136, 137]
• Decreased dopamine uptake and disrupted the precision of dopamine
transmission by increasing spontaneous dopamine release
Schizophrenia Glutamatergic neurons • Elevated levels of secreted catecholamines including dopamine,
norepinephrine, and epinephrine secretion
[88, 91]
• Increased percentage of tyrosine hydroxylase-positive neurons,
the first enzymatic step for catecholamine biosynthesis
• Decreased neuronal connectivity and numbers of neurites
Spinal muscular atrophy Motor neurons • Attenuated levels of SMN1 protein in spinal muscular atrophy iPSC
neurons, resulting in the selective degeneration of motor neurons
[96, 145]
• Decreased numbers of motor neuron survival with a reduced size
• Reduced axonal growth and neuromuscular junction formation
Rett syndrome Glutamatergic neurons • Diminished number of synapses and dendritic spines [87]
• Abnormally decreased activity-dependent calcium oscillations
• Reduced frequencies and amplitude of spontaneous synaptic
currents, reflecting fewer release sites or a decreased release
probability of neurotransmission
Phelan–McDermid syndrome Forebrain neurons • Impaired excitatory neurotransmission indicated by reduced amplitudes
and frequencies of spontaneous excitatory postsynaptic currents
[89]
• Disrupted the ratio of cellular excitation and inhibition in
Phelan–McDermid syndrome neurons
Aβ, amyloid beta; GABA, γ-aminobutyric acid; iPSC, induced pluripotent stem cell; NPC, neural progenitor cell
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neurons of Rett syndrome patients [87]. Similarly, in
iPSC-derived neurons from patients with trisomy 21, the
frequency of spontaneous neurotransmission was reduced,
although it was not specified whether excitatory or inhibi-
tory neurotransmission was affected [90]. In neurons
differentiated from Phelan–McDermid syndrome patient-
derived iPSCs, excitatory neurotransmission was impaired,
as indicated by reduced amplitudes and frequencies of
spontaneous excitatory postsynaptic currents [89]. These
models will help us to understand the molecular biology
underlying diseases and pave the way for re-regulating
dysfunctional neuronal circuits. According to safety issues
of iPSC therapy, accumulating preclinical evidence sup-
ports the effectiveness of iPSC-based cell therapy on the
selection of appropriate iPSC clones. Continuous develop-
ment of safer iPSCs has resulted from insertion-free sys-
tems and the use of new transgenes. Nevertheless, before
clinical application of iPSC-based cell therapies is achieved,
these safety concerns must be assuaged through a thor-
ough examination of the quality of both iPSCs and iPSC-
derived cells, in terms of genetic and epigenetic status,
differentiation capability both in vitro and in vivo, and
tumorigenicity [146].
Conclusions
Curing neurological diseases is a challenging task in ex-
perimental therapeutics. The incidence of neurodegener-
ative diseases has enormously increased due to a rise in
life expectancy. However, there are only symptomatic
treatments available for several reasons: a lack of know-
ledge about disease pathogeneses; limited access to tis-
sue samples for early stages of neurodegeneration; and
the inability of animal models to recapitulate all aspects
of human diseases. The development of stem cell tech-
nology provides a powerful tool in neurobiology that
might help solve these problems. The availability of hu-
man ESCs, iPSCs and iN cells enables the investigation
of diseases in unprecedented depth. Human ESCs can be
genetically modified to harbor a desired mutation and
develop a phenotype of disease. However, the incomplete
penetrance and variability among phenotypes of genetic
disease can be an obstacle for accurate disease modeling.
Bioethics and limited availability are also of concern. On
the other hand, human iPSCs or iN cells might be the
best methods available to reprogram patient cells into
neurons. They allocate the opportunity to turn back the
clock or to uncover the mechanisms underlying cause
and progression of sporadic neurodegenerative diseases
whose cause has yet to be identified [73]. There is also
great expectation for use of stem cell technology in re-
generative medicine. For instance, human iPSCs can be
prepared from the patient themselves, thereby avoiding
graft rejection. Nevertheless, major limitations fortransplantation are the delivery of neurons into the ap-
propriate location and the integration of these cells into
pre-existing circuits. Other limitations are chromo-
somal abnormalities leading to clonal variation, tera-
toma formation, and immaturity of differentiated cells.
Thus, iPSC karyotypes need to be tested, and undiffer-
entiated cells should be carefully removed prior to
therapeutic application [147]. To this end, maturation
protocols that provide iPSC models containing genetic
susceptibility in parallel with aging-related factors con-
tinue to be developed in order to accurately model late-
onset disorders [72].
Electrophysiological techniques are not the only ap-
proaches to investigate the phenotype and maturity of
stem cell-derived neurons. Genome editing technologies
are also being used to demonstrate the relationship be-
tween genotype and phenotype. Genome-wide associ-
ation studies might uncover causative or predisposing
genetic loci contributing to multifactorial disease. An-
other benefit of using stem cell-derived neurons is in
large-scale screening of pharmacological agents prevent-
ing or curing the disease. The opportunity for personal-
ized medicine is also a very promising application of
stem cell technologies in which neurons can be derived
from the same individual for whom the therapy is tai-
lored. In summary, recapitulation of human neurological
disease following stem cell-derived neuronal differenti-
ation in vitro is still a big scientific challenge. Although we
can model neuronal circuits in a dish and confirm the ex-
pression of neuronal markers and electrophysiological
functionality, we cannot yet conclude that these circuits
represent the actual connectivity and mature circuitry
present throughout the central nervous system. There is
thus the need to refine techniques aimed to produce neu-
rons in vitro that properly integrate into pre-existing cir-
cuits to assume physiological functions [148].Abbreviations
AD: Alzheimer’s disease; AP: action potential; Cm: membrane capacitance;
EEG: electroencephalography; ESC: embryonic stem cell; fMRI: functional
magnetic resonance imaging; FWHM: full width at half-maximum; GABA:
γ-aminobutyric acid; GDP: giant depolarizing potential; iN: induced neuronal;
iPSC: induced pluripotent stem cell; LTD: long-term depression; LTP: long-term
potentiation; NMDAR: N-methyl-D-aspartate receptor; NPC: neural progenitor
cell; PD: Parkinson’s disease; Rin: input resistance; RMP: resting membrane
potential; SMA: spinal muscular atrophy; τ: membrane time constant.Competing interests
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